Madison Investments released its third-quarter 2025 investor letter for the Madison Small Cap Fund, reporting a 1.3% decrease. The fund underperformed benchmarks due to stock selection issues and a speculative market. Charles River Laboratories International, Inc. (NYSE:CRL) was highlighted in the letter, with a one-month return of -14.15% and a market capitalization of $8.25 billion.

In the third quarter of 2025, Madison Small Cap Fund initiated a position in Charles River Laboratories International, Inc. (NYSE:CRL) due to its high-quality services in drug discovery and development outsourcing. The company has solid management and is poised for long-term success, with an intrinsic value of $228 per share by 2028 according to the fund.

Charles River Laboratories International, Inc. (NYSE:CRL) reported a 0.5% decrease in revenue in the third quarter of 2025 compared to the same period in 2024. While the company shows investment potential, other AI stocks may offer greater upside with less downside risk. Hedge funds like ClearBridge Growth Strategy have also shared their views on CRL.

For more insights on investor letters and stock recommendations, visit Insider Monkey. No promotional or marketing content included in the news summaries.

Read more at Yahoo Finance: What Makes Charles River Laboratories (CRL) an Investment Bet?